Imatron sells HeartScan-Pittsburgh Center

Article

Ultrafast CT developer Imatron sold another of its U.S. HeartScan coronary artery disease risk assessment centers last month, this one to the University of Pittsburgh Medical Center. The June 17 deal transferred HeartScan-Pittsburgh operations to the

Ultrafast CT developer Imatron sold another of its U.S. HeartScan coronary artery disease risk assessment centers last month, this one to the University of Pittsburgh Medical Center. The June 17 deal transferred HeartScan-Pittsburgh operations to the University of Pittsburgh’s Cardiovascular Institute, which plans to start a preventive heart care center using Imatron’s electron beam CT unit.

With its divestiture of HeartScan-Pittsburgh, South San Francisco, CA-based Imatron comes closer to its goal of focusing its efforts on marketing its ultrafast CT units, according to Lewis Meyer, CEO. The company has been seeking individual buyers for each of its centers since earlier this year, after an initial effort to sell all four centers to one buyer failed.

In February, the company sold its South San Francisco facility to Imaging Technology Group, also of South San Francisco, and a month later found a potential buyer for its Houston and Washington, DC centers in Vital Imaging Companies of Newport Beach, CA (SCAN 3/31/99 and 3/17/99). But the Vital Imaging deal fell through due to lack of financing, so Imatron continues to seek a buyer for the two centers, company executives said.

In other Imatron news, the company sold two Ultrafast CT scanners in late June, one to a German hospital and the other to a San Diego facility. The San Diego sale was financed by GE Capital under the terms of a marketing arrangement between Imatron and GE Medical Systems of Milwaukee (SCAN 6/24/98).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.